Zhejiang Starry PharmaceuticalLtd Management
Management criteria checks 2/4
Zhejiang Starry PharmaceuticalLtd's CEO is Weiyi Shen, appointed in May 2023, has a tenure of 1.58 years. directly owns 0.003% of the company’s shares, worth CN¥102.42K. The average tenure of the management team and the board of directors is 1.6 years and 1.6 years respectively.
Key information
Weiyi Shen
Chief executive officer
CN¥556.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.003% |
| Management average tenure | 1.6yrs |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
There's No Escaping Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) Muted Revenues
Sep 30
Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality
May 06Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost
Mar 12Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?
Feb 28CEO
Weiyi Shen (44 yo)
1.6yrs
Tenure
CN¥556,000
Compensation
Mr. Weiyi Shen is Vice Chairman of Zhejiang Starry Pharmaceutical Co.,Ltd. since November 01, 2021 and serves as its General Manager since May 18, 2023. He joined the Zhejiang Starry Pharmaceutical Co.,Ltd...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & GM | 1.6yrs | CN¥556.00k | 0.0027% CN¥ 102.4k | |
| Financial Director | 2yrs | CN¥269.40k | 0.00059% CN¥ 22.6k | |
| Board Secretary | 2.3yrs | CN¥316.40k | 0.0010% CN¥ 40.3k | |
| Deputy General Manager | 1.3yrs | CN¥256.50k | 0.0064% CN¥ 244.0k | |
| Deputy General Manager | 1.3yrs | CN¥544.80k | no data | |
| Accounting Supervisor | no data | no data | no data |
1.6yrs
Average Tenure
44yo
Average Age
Experienced Management: 603520's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & GM | 3.1yrs | CN¥556.00k | 0.0027% CN¥ 102.4k | |
| Director | no data | CN¥1.26m | 10.28% CN¥ 394.4m | |
| Chairman | 1.6yrs | CN¥683.50k | 10.56% CN¥ 405.2m | |
| Independent Director | 1.6yrs | CN¥60.00k | no data | |
| Supervisor | 4.7yrs | no data | no data | |
| Chairman of the Supervisory Board | 1.6yrs | no data | 0.0077% CN¥ 293.8k | |
| Supervisor | 1.6yrs | no data | 0.0022% CN¥ 83.6k | |
| Independent Director | 1.6yrs | CN¥60.00k | no data | |
| Director | 1.6yrs | no data | no data | |
| Independent Director | 1.6yrs | CN¥60.00k | no data |
1.6yrs
Average Tenure
46yo
Average Age
Experienced Board: 603520's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 21:05 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Starry Pharmaceutical Co.,Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yue Gao | Changjiang Securities Co. LTD. |
| Xu Qing Liu | Chasing Securities |
| Feifei Xu | China Merchants Securities Co. Ltd. |